This study examines the utilisation of opioid substitution therapy among a large community sample of chronic non-cancer pain patients receiving long-term opioid substitution therapy (OST).
Treatment and Intervention
Smoking cessation rates need to improve among low-socioeconomic status (low-SES) Australians if we are to reach a key national target as the health country: ≤ 9% smoking by 2020 . Recent (2013) National Drug Strategy Household Survey data show that persons from disadvantaged areas are three
This is a feasibility study to test the effectiveness of cannabidiol (CBD) for alleviating cannabis withdrawal symptoms in a 6 night inpatient detoxification program.
Technology assisted substance use interventions such as ‘high-tech’ internet-based treatments are thought to be effective; however, the relatively ‘low tech’ use of telephone counselling does not yet have an established evidence base outside of tobacco cessation.
This research project seeks to examine the patterns and costs of Pharmaceutical Benefits Scheme-subsidised opioid use, including extra-medical use, in the Australian population.
A recent randomised controlled trial found that Reduce your use was effective in assisting cannabis users to quit or cut down on their use.
Despite a high prevalence of drug and alcohol (AOD)-related morbidity among patients presenting to emergency departments, acute care settings and pre-admission clinics, previous research has found AOD-related morbidity is not commonly identified on admission.
The National Drug and Alcohol Research Centre (NDARC) have been invited to work with 5 remote NSW communities to retrospectively evaluate a suite of interventions aimed at prevention of drug and alcohol harms from 2012-2014.
This project aims to describe patterns of AAS and PIEDs use; where people are sourcing them from and why; users' experience of harms; and users' utilisation of health services.
Opioid agonist treatment is commonly initiated as a first-line treatment for individuals with pharmaceutical opioid dependence, even though much of the evidence base for the use of pharmacotherapy treatments in opioid dependence has been derived from studies conducted with primarily or exclusivel